EGFR and breast cancer: The results of a saturation radioligand binding assay revealed high affinity binding (Kd = 2.9 ± 0.7 × 10− 9 mol/L) of [177Lu]Lu-DOTA-panitumumab F(ab ́)2 to EGFR-positive MDA-MB-468 human breast cancer cells (Fig. 2).